Previous 10 | Next 10 |
home / stock / bmy / bmy articles
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally a...
New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that consider...
Bristol Myers Squibb (NYSE:BMY) has named Christopher Boerner as their new Chair of the Board of Directors and CEO. Boerner, who is set to take ove...
Bristol-Myers Squibb Co (NYSE: BMY) shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward rev...
Bristol Myers Squibb & Co (NYSE: BMY) reported better-than-expected earnings for its third quarter. Bristol Myers Squibb said revenues came in ...
Wall Street experienced a significant downturn Thursday as volatility surged, triggered by a shift in risk sentiment following a combination of mix...
U.S. stocks traded mixed this morning, following the release of several economic reports. Following the market opening Thursday, the Dow traded up ...
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q3 revenues of $10.966 billion declined 2% Y/Y, or 3% when adjusted for foreign exchan...
A somber mood looms over Wall Street, stirred by lackluster earnings reports and relentless bond yield increases. Stock futures dipped early Thursd...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...